Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page
- Check5 days agoChange DetectedThe related topics section now includes Prostate cancer and MedlinePlus Genetics, linking to educational resources.SummaryDifference0.2%

- Check12 days agoChange DetectedThe page revision tag was updated from v3.6.2 to v3.6.3. This indicates a minor site update to the page template or backend without altering the study content.SummaryDifference0.1%

- Check19 days agoChange DetectedThe revision tag was updated from v3.6.0 to v3.6.2. This indicates a minor update to the page's content or system without changing the study information.SummaryDifference0.1%

- Check33 days agoChange DetectedRecruitment status now indicates the study is no longer looking for participants. The page also adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Interventions header from 'Intervention / Treatment' to 'Intervention/Treatment' with a revision note to v3.6.0.SummaryDifference0.5%

- Check40 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the page. The main study details and user-facing information remain the same.SummaryDifference0.1%

- Check47 days agoChange DetectedThe explicit 'Prostate cancer' label and the 'MedlinePlus Genetics' related topic linkage have been removed, along with the 'related topics' header. This changes how the study's subject is presented and which educational resources are shown to users.SummaryDifference0.2%

Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.